At ASCO 2026, ecancer talks to Dr Jessica Paulus about real-world data evaluating GLP-1 receptor agonist use in patients with cancer treated within a large US oncology network.

The analysis found that patients receiving GLP-1 therapies experienced improved overall survival compared with non-users, with breast and prostate cancers accounting for the largest proportion of GLP-1 use.

Dr Paulus notes that these findings support further research into the potential role of GLP-1 therapies in cancer care and their impact on long-term patient outcomes.